Trial Profile
Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Metformin (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 11 Mar 2024 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 15 Aug 2022 Planned End Date changed from 1 Oct 2021 to 1 Oct 2023.